ribosomal protein S6 kinase A5Genealiases: MSK1 · MSPK1 · RLPK
Q-omics provides the consensus-scored RPS6KA5 profile across patient tissues and cancer cell-line models. RPS6KA5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPS6KA5 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RPS6KA5 protein abundance shows 22,762 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, THCA, and GBM as cancer lineages where RPS6KA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6KA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6KA5 survival associations across molecular data types. RPS6KA5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6KA5 RNA expression–survival associations across cancer types. High RPS6KA5 expression shows unfavorable associations in KIRP, but favorable associations in HNSC, LUSC, KIRC, LGG and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPS6KA5 RNA expression.
This table summarizes RPS6KA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RPS6KA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6KA5 shows lower tumor expression in THCA, COAD, BLCA, KICH, UCEC and LUAD. The THCA box plot shows higher RPS6KA5 RNA expression in normal versus tumor tissue (log2 FC = −1.084, t-test p < 0.001).
This table shows molecular features associated with RPS6KA5 in patient tissues and cancer cell lines. In patient samples, RPS6KA5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS6KA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
